Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 3
1(16.7%)
6Total
Phase 2(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01689194Phase 2Completed

Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer

Role: collaborator

NCT00349492Phase 3Completed

A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer

Role: lead

NCT00623558Phase 2Completed

Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

Role: collaborator

NCT00921167Phase 2Completed

A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas

Role: lead

NCT00805012Phase 2Terminated

Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Role: collaborator

NCT00830245Phase 2Terminated

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Role: lead

All 6 trials loaded